CSPC Pharmaceutical initiates China Phase III trial of SYS6043 in platinum-resistant ovarian cancer

• Phase III trial of SYS6043 for platinum-resistant advanced ovarian cancer initiated at the first clinical center in China.
• CSPC Pharmaceutical Group launched a randomized, multicenter, open-label study versus investigator’s choice chemotherapy; recruitment began following China clearance in July 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260716-12247191), on July 16, 2026, and is solely responsible for the information contained therein.